In the complex landscape of oncology drug development and commercialization, selecting the right conferences for executives, business development, and investor relations teams has become an increasingly strategic decision. The THMA Oncology Forum has carved out a unique niche with its highly focused format and, most notably, its remarkable one-to-one health system to industry ratio. For companies like Bristol Myers Squibb, Pfizer, and Amgen, this shaping of direct access to health system decision-makers offers more than just networking; it provides tangible pathways to adoption and formulary decision influence—critical factors in oncology adoption strategy.. Pretty simple.
Understanding the THMA Oncology Forum
The THMA Oncology Forum is a specialized executive-level conference focusing uniquely on the dynamic dialogue between pharmaceutical/biotech innovators and U.S. health system and hospital payer providers. Hosted annually, the event's core value proposition stems from its distinctive attendee composition and meticulously curated agenda aimed at accelerating oncology adoption within health systems.
Unlike typical oncology conferences that primarily gather researchers, clinicians, or commercial sales teams, the THMA Oncology Forum brings together:
- Senior executives from major oncology-focused pharmaceutical companies and biotech firms Leadership from health systems and hospital networks responsible for oncology care delivery and formulary decisions Capital markets participants evaluating investment and financing opportunities in oncology innovation
This composition results in an atmosphere that goes beyond broad discussions about innovation, turning instead toward the practical realities of oncology adoption strategy, utilization management, and market access within health systems.
The 1-to-1 Health System to Industry Ratio: Why It Matters
One of the biggest draws—and what sets the THMA Oncology Forum apart—is its commitment to maintaining close to a 1:1 ratio between health system representatives and industry attendees. This balance is rare in oncology conferences where industry attendees heavily outnumber provider or health system leadership.
So why is this 1-to-1 ratio such a big deal?
Meaningful Partnering and Dialogue: With nearly equal numbers from both sides, each industry executive has a better chance to connect directly and engage in deeper discussions with decision-makers responsible for care delivery and formulary choices. Focused Executive Time and Priorities: Health system leaders commit time to attend knowing they will be matched with industry teams serious about alignment and understanding adoption challenges, not just sales pitches. Efficient Meeting Math: From a business development vantage point, achieving a high hit rate in one-to-one meetings is critical. A balanced ratio maximizes the relevance and quality of each interaction, reducing the 'noise' and agenda padding common at larger, less curated events.Objective-First Executive Conference Selection
As someone who has staffed and produced partnering programs for over a decade, I always urge teams to focus on meeting math before approving travel or budget. What does that look like at the THMA Oncology Forum?
- Clear Objective: If your goal is to accelerate negotiations or partnerships with health systems around oncology product adoption, this forum is likely ‘worth it’. Targeted Attendee Profiles: Unlike mega-events where you might need dozens of 1-to-1 meetings to find a few relevant counterparts, THMA’s ratio means fewer meetings but higher quality and relevance. Pre-Scheduled 1-to-1 Meetings: Using advanced partnering platforms like the BIO Partnering platform and the LSX partnering platform, companies schedule many meetings weeks in advance. This pre-planning ensures executive time is used efficiently and minimizes ad hoc networking.
For instance, the BIO Partnering platform offers an intuitive interface for companies to schedule meetings with relevant health system leaders well in advance. Meanwhile, LSX’s partnering tools complement this by facilitating one-to-one meeting scheduling that aligns commercial, access, and medical affairs teams’ goals with payer and provider executives.
Capital Markets and Investor Access: An Underrated Advantage
The forum is also https://www.biopharmaboardroom.com/news/71/4854/pharmaceutical-conferences-for-executives-in-2026.html a hotspot for capital markets activities. With oncology innovation rapidly evolving, investors and venture capitalists are paying close attention to not just product pipelines, but also market access and adoption risks. Executives from firms running oversubscribed fundraising rounds, such as the recent $5 Million fundraise by PlaqueTec Limited (featured prominently in industry editorial picks), utilize the forum to showcase commercial progress and early adoption signals.
Investors appreciate being able to ask incisive questions directly to both company executives and health system stakeholders within the same setting. Such transparency helps reduce risk perception and can be pivotal for fundraising success.
Health System Adoption and Formulary Decision-Makers Front and Center
Another unique aspect of the THMA Oncology Forum is its ability to convene real decision-makers—typically hard to access outside of direct sales or contracting channels. These attendees are:
- Chief Pharmacy Officers Oncology Medical Directors Health System Market Access Leaders Formulary Committee Members
By bringing these stakeholders into direct conversation with industry executives from Bristol Myers Squibb, Pfizer, Amgen, and other leaders, the event creates a rare platform for discussing formulary criteria, value demonstration, outcomes management, and real-world evidence needs.
This direct feedback loop enables companies to refine their oncology adoption strategy in close alignment with payer-provider expectations, accelerating time to formulary acceptance and, ultimately, patient access.
Table: Comparing Typical Oncology Conference vs THMA Oncology Forum
Feature Typical Oncology Conference THMA Oncology Forum Health System to Industry Ratio Often 1:5 or worse Approximately 1:1 Focus of Interaction Research and Clinical Science Adoption Strategy and Formulary Decisions Use of Partnering Platforms Varies, often limited pre-scheduling Extensive use of BIO & LSX partnering platforms Investor and Capital Markets Access Limited explicit engagement Integrated capital markets presence and deal flow Meeting Quality Broad, mixed relevance Targeted, pre-scheduled, high relevanceFinal Thoughts: Is the THMA Oncology Forum Worth Your Team’s Time?
From my experience and ongoing tracking of event ROI, the THMA Oncology Forum stands out as a focused event for executives with serious objectives tied to oncology product adoption within health systems and capital markets. The hallmark one-to-one health system to industry ratio is not a gimmick but a deliberate design to enable impactful, actionable meetings.
For pharmaceutical giants like Bristol Myers Squibb, Pfizer, and Amgen—who operate on large scales but need finely tuned health system partnerships—the THMA Oncology Forum offers a welcomely intimate, high-touch environment. For biotech innovators navigating capital raises—such as those who have recently closed oversubscribed rounds like PlaqueTec Limited's $5 million fundraise—the forum provides invaluable credibility and engagement with both investor and payer-provider audiences.
You know what's funny? to maximize the value from attendance, leveraging partnering platforms like bio partnering and lsx for pre-scheduled meetings is essential. This approach mitigates the risk of hitting too many “generic” networking sessions and focuses executive time on deliberate conversations that can advance commercial goals and investor relations.
Ultimately, when considering oncology-related conferences, ask yourself: What is my meeting math? Does the event align tightly with my business objectives? Will I meet the right people in a meaningful 1-to-1 format? If the answer is yes, the THMA Oncology Forum is more than just another date in your calendar—it’s a strategic platform for oncology adoption success.